ClinicalTrials.gg
CompletedNCT03915067Updated May 3, 2023Results posted

BOTOX® for the Treatment of Platysma Prominence

A Phase 2 interventional study of BOTOX® purified neurotoxin complex and Placebo in Platysma Prominence, sponsored by Allergan. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.

02

Conditions studied

  • Platysma Prominence
03

In context

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period
  • A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization), not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to follow the studies guidance during the treatment and follow-up period through study exit.
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this study's protocol

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that may put the participant at increased medical risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)
  • Anticipated need for surgery or overnight hospitalization during the study
  • Current enrollment in an drug or device study or participation in such a study within 30 days of entry into this study
  • Females who are pregnant, nursing, or planning a pregnancy during the study
  • Known immunization or to any botulinum toxin serotype
  • History of alcohol or drug abuse within 12 months of the study
  • Participant has tattoos, jewelry, or clothing that cannot be removed, and that obscure the neck
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received matching placebo as superficial intramuscular injections administered to the platysma muscle on Day 1.

    Drug: Placebo

  • Experimental
    BOTOX® Low Dose

    Participants received BOTOX® Low Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.

    Drug: BOTOX® purified neurotoxin complex

  • Active comparator
    BOTOX® High Dose

    Participants received BOTOX® High Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.

    Drug: BOTOX® purified neurotoxin complex

Interventions

  • BOTOX® superficial intramuscular injections.

    Also known as: Botulinum toxin type A purified neurotoxin complex

  • DrugPlacebo

    Placebo injections.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS)

    The investigator evaluated the participant's platysma prominence severity using a 5-grade scale C-APPS at maximum contraction where 1= minimal, and 5= extreme. Higher values indicate worsening condition. Data is reported for participants who achieved at least a 1-grade improvement rated on the C-APPS. Percentages are rounded off to whole number at the nearest decimal. Cochran-Mantel-Haenszel (CMH) chi-squared test was used for analysis.

    Time frame: Day 14

  2. Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. Treatment-emergent adverse events are defined as any event that began or worsened in severity on or after the first dose of study drug or any AE that was present before the first dose of study intervention, but increased in severity or became serious after the first dose of study intervention.

    Time frame: From the first dose of study drug up to end of study (up to Day 120)

  3. Pulse Rate at Baseline

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline (Day 1)

  4. Change From Baseline in Pulse Rate at Day 7

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline; Day 7

  5. Change From Baseline in Pulse Rate at Day 14

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline; Day 14

  6. Change From Baseline in Pulse Rate at Day 30

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline; Day 30

  7. Change From Baseline in Pulse Rate at Day 60

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline; Day 60

  8. Change From Baseline in Pulse Rate at Day 90

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline; Day 90

  9. Change From Baseline in Pulse Rate at Day 120

    Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

    Time frame: Baseline; Day 120

  10. Systolic and Diastolic Blood Pressure (BP) at Baseline

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline (Day 1)

  11. Change From Baseline in Systolic and Diastolic BP at Day 7

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline; Day 7

  12. Change From Baseline in Systolic and Diastolic BP at Day 14

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline; Day 14

  13. Change From Baseline in Systolic and Diastolic BP at Day 30

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline; Day 30

  14. Change From Baseline in Systolic and Diastolic BP at Day 60

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline; Day 60

  15. Change From Baseline in Systolic and Diastolic BP at Day 90

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline; Day 90

  16. Change From Baseline in Systolic and Diastolic BP at Day 120

    Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

    Time frame: Baseline; Day 120

  17. Respiratory Rate at Baseline

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline (Day 1)

  18. Change From Baseline in Respiratory Rate at Day 7

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline; Day 7

  19. Change From Baseline in Respiratory Rate at Day 14

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline; Day 14

  20. Change From Baseline in Respiratory Rate at Day 30

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline; Day 30

  21. Change From Baseline in Respiratory Rate at Day 60

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline; Day 60

  22. Change From Baseline in Respiratory Rate at Day 90

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline; Day 90

  23. Change From Baseline in Respiratory Rate at Day 120

    Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

    Time frame: Baseline; Day 120

Secondary outcomes

  1. Percentage of Participants With at Least a 1-Grade Improvement at Day 14 as Rated by Participant Using the Participant Allergan Platysma Prominence Scale (P-APPS)

    The participants evaluated their own Platysma Prominence severity using a 5-grade scale where 1= minimal, and 5= extreme. Higher values indicate worsening conditions. Data is reported for participants who achieved at least a 1-grade improvement rated on the P-APPS. Percentages are rounded off to whole number at the nearest decimal. CMH chi-squared test was used for analysis.

    Time frame: Day 14

07

Results

Posted May 3, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboBOTOX® Low DoseBOTOX® High Dose
Started575955
Modified intent-to-treat (mitt) population535853
Safety population565954
Completed475049
Not completed1096
Withdrew: Adverse event001
Withdrew: Withdrawal by subject430
Withdrew: Lost to follow-up320
Withdrew: Protocol deviation001
Withdrew: Covid-19 related issues244
Withdrew: Randomized with incorrect c-apps100

Outcome measures

PrimaryPercentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS)

The investigator evaluated the participant's platysma prominence severity using a 5-grade scale C-APPS at maximum contraction where 1= minimal, and 5= extreme. Higher values indicate worsening condition. Data is reported for participants who achieved at least a 1-grade improvement rated on the C-APPS. Percentages are rounded off to whole number at the nearest decimal. Cochran-Mantel-Haenszel (CMH) chi-squared test was used for analysis.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS)
percentage of participantsPlaceboBOTOX® Low DoseBOTOX® High Dose
Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS)12.0 (3.0 to 21.0)77.8 (66.7 to 88.9)88.2 (79.4 to 97.1)
Statistical analysis
  • Placebo vs BOTOX® Low Dose · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from CMH model stratified by investigator site and C-APPS at Day 1.) · Rate difference: 65.8 · 95% CI 51.5 to 80.1
  • Placebo vs BOTOX® High Dose · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from CMH model stratified by investigator site and C-APPS at Day 1.) · Rate difference: 76.2 · 95% CI 63.6 to 88.9
PrimaryNumber of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. Treatment-emergent adverse events are defined as any event that began or worsened in severity on or after the first dose of study drug or any AE that was present before the first dose of study intervention, but increased in severity or became serious after the first dose of study intervention.

Time frame:
From the first dose of study drug up to end of study (up to Day 120)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)
ParticipantsPlaceboBOTOX® Low DoseBOTOX® High Dose
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)131414
PrimaryPulse Rate at Baseline

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline (Day 1)
Reported as:
Mean · beats per minute (beats/min)
Pulse Rate at Baseline
beats per minute (beats/min)PlaceboBOTOX® Low DoseBOTOX® High Dose
Pulse Rate at Baseline73.0 ± 10.7774.4 ± 9.7773.6 ± 10.66
PrimaryChange From Baseline in Pulse Rate at Day 7

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline; Day 7
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 7
beats/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Pulse Rate at Day 71.0 ± 8.19-0.5 ± 6.761.2 ± 13.86
PrimaryChange From Baseline in Pulse Rate at Day 14

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline; Day 14
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 14
beats/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Pulse Rate at Day 140.4 ± 8.76-1.4 ± 7.961.3 ± 10.49
PrimaryChange From Baseline in Pulse Rate at Day 30

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline; Day 30
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 30
beats/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Pulse Rate at Day 300.1 ± 11.57-0.9 ± 7.09-0.5 ± 10.22
PrimaryChange From Baseline in Pulse Rate at Day 60

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline; Day 60
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 60
beats/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Pulse Rate at Day 600.4 ± 11.140.3 ± 8.24-2.1 ± 11.62
PrimaryChange From Baseline in Pulse Rate at Day 90

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline; Day 90
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 90
beats/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Pulse Rate at Day 901.1 ± 10.58-0.9 ± 8.760.0 ± 9.45
PrimaryChange From Baseline in Pulse Rate at Day 120

Participants were seated for at least 5 minutes, and pulse was counted over 60 seconds and recorded.

Time frame:
Baseline; Day 120
Reported as:
Mean · beats/min
Change From Baseline in Pulse Rate at Day 120
beats/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Pulse Rate at Day 1200.5 ± 12.39-0.4 ± 9.240.8 ± 11.77
PrimarySystolic and Diastolic Blood Pressure (BP) at Baseline

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline (Day 1)
Reported as:
Mean · millimeters of mercury (mmHg)
Systolic and Diastolic Blood Pressure (BP) at Baseline
millimeters of mercury (mmHg)PlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic Blood Pressure116.6 ± 12.62119.7 ± 14.96120.4 ± 13.38
Diastolic Blood Pressure77.2 ± 9.1176.6 ± 9.2677.6 ± 8.81
PrimaryChange From Baseline in Systolic and Diastolic BP at Day 7

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline; Day 7
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic BP at Day 7
mmHgPlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic BP1.2 ± 11.491.7 ± 13.37-2.0 ± 11.14
Diastolic BP-0.5 ± 6.660.3 ± 8.430.2 ± 8.57
PrimaryChange From Baseline in Systolic and Diastolic BP at Day 14

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline; Day 14
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic BP at Day 14
mmHgPlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic BP0.0 ± 9.291.9 ± 13.27-1.7 ± 10.17
Diastolic BP-1.0 ± 6.991.1 ± 8.69-0.5 ± 7.41
PrimaryChange From Baseline in Systolic and Diastolic BP at Day 30

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline; Day 30
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic BP at Day 30
mmHgPlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic BP-2.0 ± 9.25-0.7 ± 13.71-2.8 ± 9.56
Diastolic BP-1.3 ± 7.460.6 ± 8.77-0.8 ± 9.01
PrimaryChange From Baseline in Systolic and Diastolic BP at Day 60

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline; Day 60
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic BP at Day 60
mmHgPlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic BP-1.2 ± 9.142.2 ± 14.49-2.6 ± 15.00
Diastolic BP-0.4 ± 6.501.9 ± 10.03-2.4 ± 9.80
PrimaryChange From Baseline in Systolic and Diastolic BP at Day 90

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline; Day 90
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic BP at Day 90
mmHgPlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic BP1.4 ± 11.40-0.3 ± 11.62-2.7 ± 11.89
Diastolic BP-2.4 ± 8.520.6 ± 7.14-3.2 ± 10.18
PrimaryChange From Baseline in Systolic and Diastolic BP at Day 120

Participants were seated for at least 5 minutes, and systolic and diastolic BP was measured.

Time frame:
Baseline; Day 120
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic BP at Day 120
mmHgPlaceboBOTOX® Low DoseBOTOX® High Dose
Systolic BP0.6 ± 12.050.1 ± 14.11-1.3 ± 10.27
Diastolic BP-0.7 ± 9.92-0.4 ± 10.43-0.5 ± 9.11
PrimaryRespiratory Rate at Baseline

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline (Day 1)
Reported as:
Mean · breaths per minute (breaths/min)
Respiratory Rate at Baseline
breaths per minute (breaths/min)PlaceboBOTOX® Low DoseBOTOX® High Dose
Respiratory Rate at Baseline15.6 ± 2.5315.5 ± 2.6615.6 ± 2.51
PrimaryChange From Baseline in Respiratory Rate at Day 7

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline; Day 7
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate at Day 7
breaths/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Respiratory Rate at Day 7-0.1 ± 1.730.1 ± 1.80-0.2 ± 1.65
PrimaryChange From Baseline in Respiratory Rate at Day 14

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline; Day 14
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate at Day 14
breaths/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Respiratory Rate at Day 14-0.2 ± 1.20-0.1 ± 2.050.0 ± 1.55
PrimaryChange From Baseline in Respiratory Rate at Day 30

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline; Day 30
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate at Day 30
breaths/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Respiratory Rate at Day 30-0.3 ± 1.700.5 ± 1.860.0 ± 1.63
PrimaryChange From Baseline in Respiratory Rate at Day 60

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline; Day 60
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate at Day 60
breaths/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Respiratory Rate at Day 60-0.2 ± 1.83-0.1 ± 1.690.2 ± 1.83
PrimaryChange From Baseline in Respiratory Rate at Day 90

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline; Day 90
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate at Day 90
breaths/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Respiratory Rate at Day 90-0.3 ± 1.85-0.1 ± 2.00-0.2 ± 2.04
PrimaryChange From Baseline in Respiratory Rate at Day 120

Participants were seated for at least 5 minutes, and breaths were counted for 30 seconds and multiplied by 2.

Time frame:
Baseline; Day 120
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate at Day 120
breaths/minPlaceboBOTOX® Low DoseBOTOX® High Dose
Change From Baseline in Respiratory Rate at Day 120-0.7 ± 1.71-0.2 ± 2.09-0.3 ± 1.85
SecondaryPercentage of Participants With at Least a 1-Grade Improvement at Day 14 as Rated by Participant Using the Participant Allergan Platysma Prominence Scale (P-APPS)

The participants evaluated their own Platysma Prominence severity using a 5-grade scale where 1= minimal, and 5= extreme. Higher values indicate worsening conditions. Data is reported for participants who achieved at least a 1-grade improvement rated on the P-APPS. Percentages are rounded off to whole number at the nearest decimal. CMH chi-squared test was used for analysis.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1-Grade Improvement at Day 14 as Rated by Participant Using the Participant Allergan Platysma Prominence Scale (P-APPS)
percentage of participantsPlaceboBOTOX® Low DoseBOTOX® High Dose
Percentage of Participants With at Least a 1-Grade Improvement at Day 14 as Rated by Participant Using the Participant Allergan Platysma Prominence Scale (P-APPS)18.0 (7.4 to 28.6)75.9 (64.5 to 87.3)88.2 (79.4 to 97.1)
Statistical analysis
  • Placebo vs BOTOX® Low Dose · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was derived from CMH model stratified by investigator site and P-APPS at Day 1.) · Rate difference: 57.9 · 95% CI 42.3 to 73.5
  • Placebo vs BOTOX® High Dose · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from CMH model stratified by investigator site and P-APPS at Day 1.) · Rate difference: 70.2 · 95% CI 56.4 to 84.1

Adverse events

Collected over All cause mortality is reported from enrollment to end of study; median time on follow up was 128.0, 127.0 and 129.0 days for placebo, BOTOX low dose and BOTOX high dose, respectively. TEAEs and SAEs were collected from first dose of study drug until 120 days after last dose of study drug; mean duration on study drug was 1 day for placebo, BOTOX low dose and BOTOX high dose, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/57 (0%)0/56 (0%)10/56 (17.9%)
BOTOX® Low Dose0/59 (0%)2/59 (3.4%)6/59 (10.2%)
BOTOX® High Dose0/55 (0%)0/54 (0%)8/54 (14.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboBOTOX® Low DoseBOTOX® High Dose
THROMBOCYTOSISBlood and lymphatic system disorders0/561/590/54
APPENDICITISInfections and infestations0/561/590/54
Most frequent other events
Most frequent other events
EventPlaceboBOTOX® Low DoseBOTOX® High Dose
MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders0/560/596/54
INJECTION SITE BRUISINGGeneral disorders4/564/593/54
INJECTION SITE HAEMORRHAGEGeneral disorders3/562/591/54
NASOPHARYNGITISInfections and infestations3/560/591/54

Baseline characteristics

mITT population included all randomized participants who had at least 1 post-baseline assessment of the primary efficacy parameter, the C-APPS, as described in the protocol.

Age, Continuous
Age, Continuous(years)PlaceboBOTOX® Low DoseBOTOX® High DoseTotal
Mean49.3 ± 9.5951.8 ± 9.1648.6 ± 10.2150.0 ± 9.69
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBOTOX® Low DoseBOTOX® High DoseTotal
Female525450156
Male1438
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBOTOX® Low DoseBOTOX® High DoseTotal
Hispanic or Latino56617
Not Hispanic or Latino485247147
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBOTOX® Low DoseBOTOX® High DoseTotal
American Indian or Alaska Native0000
Asian1135
Native Hawaiian or Other Pacific Islander2103
Black or African American1012
White495649154
More than one race0000
Unknown or Not Reported0000
08

Study locations

12 sites
  • Skin Care and Laser Physicians of Beverly Hills /ID# 236518
    Los Angeles, California 90069, United States
  • Skin Research Institute LLC /ID# 238126
    Coral Gables, Florida 33146-1837, United States
  • DeNova Research /ID# 238165
    Chicago, Illinois 60611, United States
  • MD Laser Skin & Vein /ID# 234532
    Hunt Valley, Maryland 21030, United States
  • The Center for Dermatology Cosmetics & Laser Surgery /ID# 235624
    Mount Kisco, New York 10549-3028, United States
  • The Practice of Brian S. Biesman MD PLLC /ID# 234461
    Nashville, Tennessee 37203, United States
  • Dallas Plastic Surgery Institute /ID# 236528
    Dallas, Texas 75231, United States
  • Humphrey Cosmetic Dermatology /ID# 236591
    Vancouver, British Columbia V5Z 4E1, Canada
  • Pacific Derm /ID# 238236
    Vancouver, British Columbia V6H 4E1, Canada
  • Dermetics Cosmetic Dermatology /ID# 236899
    Burlington, Ontario L7N 3N2, Canada
  • Sweat Clinics of Canada /ID# 236590
    Toronto, Ontario M5R 3N8, Canada
  • Bertucci MedSpa Inc. /ID# 236523
    Woodbridge, Ontario L4L 8E2, Canada
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Apr 2020, 11 months.

Results were first posted in May 2023, 3 years after primary completion. A results delay was requested in Apr 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 16, 2019
StartActual
Apr 23, 2019
Primary completionActual
Apr 16, 2020
CompletionActual
Apr 16, 2020
Results delay requested
Apr 12, 2021
Results first posted
May 3, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03915067
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Apr 23, 2019
Primary completion
Apr 16, 2020
Completion
Apr 16, 2020
Results posted
May 3, 2023
Last update
May 3, 2023

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion